Allogene Therapeutics logo

Allogene Therapeutics Share Price Today

(NASDAQ: ALLO)

Allogene Therapeutics share price is $1.55 & ₹132.46 as on 26 Apr 2025, 2.30 'hrs' IST

$1.55

-0.02

(-1.27%)

Market is closed - opens 7 PM, 28 Apr 2025

View live Allogene Therapeutics share price in Dollar and Rupees. Guide to invest in Allogene Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Allogene Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Allogene Therapeutics share price movements

  • Today's Low: $1.52
    Today's High: $1.59

    Day's Volatility :4.1%

  • 52 Weeks Low: $1.23
    52 Weeks High: $3.78

    52 Weeks Volatility :67.46%

Allogene Therapeutics (ALLO) Returns

PeriodAllogene Therapeutics, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-18.65%
-4.8%
0.0%
6 Months
-41.42%
-7.5%
0.0%
1 Year
-45.67%
-1.8%
0.0%
3 Years
-81.29%
2.1%
-9.5%

Allogene Therapeutics (ALLO) Key Statistics

in dollars & INR

Previous Close
$1.57
Open
$1.56
Today's High
$1.585
Today's Low
$1.52
Market Capitalization
$349.8M
Today's Volume
$1.6M
52 Week High
$3.78
52 Week Low
$1.23
Revenue TTM
$22.0K
EBITDA
$-243.8M
Earnings Per Share (EPS)
$-1.32
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-55.13%

How to invest in Allogene Therapeutics Stock (ALLO) from India?

It is very easy for Indian residents to invest directly in Allogene Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Allogene Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Allogene Therapeutics or ALLO on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Allogene Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Allogene Therapeutics shares which would translate to 0.551 fractional shares of Allogene Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Allogene Therapeutics, in just a few clicks!

Returns in Allogene Therapeutics (ALLO) for Indian investors in Rupees

The Allogene Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Allogene Therapeutics investment value today

Current value as on today

₹56,771

Returns

₹43,229

(-43.23%)

Returns from Allogene Therapeutics Stock

₹45,804 (-45.8%)

Dollar Returns

₹2,575 (+2.58%)

Indian investors sentiment towards Allogene Therapeutics (ALLO)

-71%

Period: Mar 26, 2025 to Apr 25, 2025. Change in 30 Days versus previous period

Search interest for Allogene Therapeutics Stock from India on INDmoney has decreased by -71% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Allogene Therapeutics

  • FMR Inc

    10.94%

  • Pfizer Inc

    10.14%

  • TPG GP A, LLC

    8.61%

  • BlackRock Inc

    8.31%

  • Vanguard Group Inc

    3.68%

  • State Street Corp

    3.34%

Analyst Recommendation on Allogene Therapeutics

Rating
Trend

Buy

    73%Buy

    26%Hold

    0%Sell

Based on 23 Wall street analysts offering stock ratings for Allogene Therapeutics(by analysts ranked 0 to 5 stars)

Analyst Forecast on Allogene Therapeutics Stock (ALLO)

What analysts predicted

Upside of 492.37%

Target:

$9.18

Current:

$1.55

Insights on Allogene Therapeutics Stock (Ticker Symbol: ALLO)

  • Price Movement

    In the last 1 year, ALLO stock has moved down by -45.0%
  • Increasing Revenue

    Revenue is up for the last 2 quarters, 21.0K → 22.0K (in $), with an average increase of 4.6% per quarter
  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -66.35M → -59.93M (in $), with an average increase of 5.4% per quarter
  • ALLO vs ONC (1 yr)

    In the last 1 year, Beone Medicines Ltd has given 72.4% return, outperforming this stock by 117.4%
  • ALLO vs VRTX (3 yr)

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 57.3% return, outperforming this stock by 138.4%

Allogene Therapeutics Technicals Summary

Sell

Neutral

Buy

Allogene Therapeutics is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Allogene Therapeutics (ALLO) Vs Peers

Returns
Ratio's
Overview
Company Name1 Month6 Month1 Year3 Years5 Years
Allogene Therapeutics, Inc. logo
0.64%
-41.42%
-45.67%
-81.29%
-94.54%
Regeneron Pharmaceuticals, Inc. logo
-5.67%
-35.41%
-32.09%
-10.95%
9.54%
Beone Medicines Ltd logo
-2.45%
17.93%
66.79%
62.33%
55.25%
Vertex Pharmaceuticals Incorporated logo
-2.01%
3.38%
23.9%
84.27%
83.41%
Alnylam Pharmaceuticals, Inc. logo
-10.48%
-15.44%
69.29%
56.6%
70.01%

About Allogene Therapeutics

Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma. In addition, it provides clinical-stage products, such as ALLO-501, cema-cel, ALLO-316, ALLO-329, ALLO-715, and ALLO-605; DLL3 for the treatment of small cell lung cancer; Claudin 18.2 for the treatment of gastric and pancreatic cancer; and FLT3 for the treatment of acute myeloid leukemia. The company has license and collaboration agreements with Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Organization
Allogene Therapeutics
Employees
226
CEO
Dr. David D. Chang M.D., Ph.D.
Industry
Health Technology

Management People of Allogene Therapeutics

NameTitle
Dr. Arie S. Belldegrun F.A.C.S., M.D.
Co-Founder & Executive Chairman
Dr. David D. Chang M.D., Ph.D.
Co-Founder, President, CEO & Director
Mr. Joshua A. Kazam
Co-Founder & Director
Dr. Zachary J. Roberts M.D., Ph.D.
Executive VP of Research & Development and Chief Medical Officer
Mr. Geoffrey M. Parker
Executive VP & CFO
Mr. Benjamin M. Beneski
Senior VP & Chief Technical Officer
Mr. Earl M. Douglas Esq.
Senior VP, General Counsel, Compliance Officer & Corporate Secretary
Ms. Susan R. Lundeen
Chief People Officer
Ms. Christine Cassiano
Executive VP, Chief Corporate Affairs & Brand Strategy Officer
Ms. Annie Yoshiyama
SVP & Corporate Controller

Important FAQs about investing in ALLO Stock from India :

What is Allogene Therapeutics share price today?

Allogene Therapeutics share price today stands at $1.55, Open: $1.56 ; Previous Close: $1.57 ; High: $1.59 ; Low: $1.52 ; 52 Week High: $3.78 ; 52 Week Low: $1.23.

The stock opens at $1.56, after a previous close of $1.57. The stock reached a daily high of $1.59 and a low of $1.52, with a 52-week high of $3.78 and a 52-week low of $1.23.

Can Indians buy Allogene Therapeutics shares?

Yes, Indians can invest in the Allogene Therapeutics (ALLO) from India.

With INDmoney, you can buy Allogene Therapeutics at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Allogene Therapeutics at zero transaction cost.

How can I buy Allogene Therapeutics shares from India?

It is very easy to buy Allogene Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Allogene Therapeutics (ALLO) be purchased?

Yes, you can buy fractional shares of Allogene Therapeutics with INDmoney app.

What are the documents required to start investing in Allogene Therapeutics stocks?

To start investing in Allogene Therapeutics, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Allogene Therapeutics Stock (ALLO)?

Today’s highest price of Allogene Therapeutics (ALLO) is $1.59.

Today’s lowest price of Allogene Therapeutics (ALLO) is $1.52.

What is today's market capitalisation of Allogene Therapeutics?

Today's market capitalisation of Allogene Therapeutics ALLO is 349.8M

What is the 52 Week High and Low Range of Allogene Therapeutics Stock (ALLO)?

  • 52 Week High

    $3.78

  • 52 Week Low

    $1.23

What are the historical returns of Allogene Therapeutics (ALLO)?

  • 1 Month Returns

    0.64%

  • 3 Months Returns

    -41.42%

  • 1 Year Returns

    -45.67%

  • 5 Years Returns

    -94.54%

Who is the Chief Executive Officer (CEO) of Allogene Therapeutics ?

Dr. David D. Chang M.D., Ph.D. is the current Chief Executive Officer (CEO) of Allogene Therapeutics.